The catch-22 of limited Food and Drug Administration approval for connective tissue disease therapies

Michelle S Min; Bina Kassamali; Daniel R Mazori; Ruth Ann Vleugels; Joseph F Merola; Gabriela Cobos; Avery H LaChance

doi:10.1016/j.jaad.2021.03.103

The catch-22 of limited Food and Drug Administration approval for connective tissue disease therapies

J Am Acad Dermatol. 2021 Aug;85(2):517-519. doi: 10.1016/j.jaad.2021.03.103. Epub 2021 Apr 3.

Authors

Michelle S Min¹, Bina Kassamali¹, Daniel R Mazori¹, Ruth Ann Vleugels¹, Joseph F Merola², Gabriela Cobos¹, Avery H LaChance³

Affiliations

¹ Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
² Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
³ Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: [email protected].

PMID: 33823201
DOI: 10.1016/j.jaad.2021.03.103

No abstract available

Keywords: Raynaud's; connective tissue disease; dermatomyositis; health policy prior authorization; lupus erythematosus; morphea; patient access; systemic sclerosis; vasculitis.

MeSH terms

Adrenal Cortex Hormones / therapeutic use*
Connective Tissue Diseases / therapy*
Drug Approval*
Humans
United States

Substances

Adrenal Cortex Hormones